23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
1 citations
,
January 2024 in “Medicine” Taohong Siwu Decoction may help treat deep vein thrombosis by reducing inflammation.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
August 2022 in “Tissue Engineering Part A” Advancements in skin treatment and wound healing include promising gene therapy, 3D skin models, and potential new therapies.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
16 citations
,
December 2012 in “Bioinformation” Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
5 citations
,
March 2025 in “World Journal of Urology” Digital health technology improves health and medication adherence in kidney transplant patients.
7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
February 2022 in “Scientia Pharmaceutica” Different hair loss treatment ingredients work well with TrichoTech™ vehicles for 3 to 6 months, making them good for use in hair treatments.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
130 citations
,
October 2006 in “Allergy” Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
July 2025 in “Journal of the Pakistan Medical Association” Combining TCA with 5-FU is more effective and safer for treating keloids than TCA alone.
9 citations
,
September 2018 in “Journal of Photochemistry and Photobiology B-biology” A hair-growth formula with cystine and thiamin helps protect skin cells against UV damage and improves their growth.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
February 2006 in “Inpharma Weekly” May 2026 in “Chemical Engineering Journal”
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.